title: Relationships between serum leptin level and severity of positive symptoms in schizophrenia.
abstract: The adipocytokine leptin is a key mediator of energy homeostasis. Recent papers have suggested that leptin may also have roles in the brain however it is unclear whether leptin is connected to symptoms of mental disorders. In this study, we sought to clarify the relationships between serum leptin level and psychopathology in schizophrenia (SZ) patients. The severity of positive symptoms inversely correlated with the serum leptin levels among SZ patients. There was no correlation between leptin levels and negative symptoms or neurocognition. Our data suggest a role of leptin in SZ positive symptoms.
authors.affiliation: Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
authors.forename: Yoichiro
authors.initials: Y
authors.lastname: Takayanagi
authors.forename: Nicola G
authors.initials: NG
authors.lastname: Cascella
authors.forename: Debby
authors.initials: D
authors.lastname: Santora
authors.forename: Patricia E
authors.initials: PE
authors.lastname: Gregory
authors.forename: Akira
authors.initials: A
authors.lastname: Sawa
authors.forename: William W
authors.initials: WW
authors.lastname: Eaton
mesh_terms: D000328:Adult; D001526:Behavioral Symptoms / Q000097:blood* / Q000378:metabolism; D003071:Cognition / Q000502:physiology*; D005260:Female; D006801:Humans; D020738:Leptin / Q000097:blood* / Q000378:metabolism; D008297:Male; D012559:Schizophrenia / Q000097:blood* / Q000378:metabolism
chemical_list: D020738:Leptin
keywords: Cognitive function; Leptin; Metabolic syndrome; Negative symptom; Positive symptoms; Schizophrenia
references.citation: Neuropsychopharmacology. 2006 Sep;31(9):2033-46
references.pmid: 16641947
references.citation: Diabetes Care. 1999 Jul;22(7):1092-6
references.pmid: 10388973
references.citation: Br J Psychiatry. 2009 Oct;195(4):286-93
references.pmid: 19794194
references.citation: J Clin Psychiatry. 2003 May;64(5):598-604
references.pmid: 12755665
references.citation: Neurobiol Aging. 2012 Aug;33(8):1730-43
references.pmid: 21763035
references.citation: J Clin Invest. 2008 Jul;118(7):2380-3
references.pmid: 18568083
references.citation: Cell Metab. 2009 Aug;10(2):89-98
references.pmid: 19656487
references.citation: Schizophr Bull. 2003;29(1):15-31
references.pmid: 12908658
references.citation: Obes Surg. 2001 Jun;11(3):252-3
references.pmid: 11433895
references.citation: Schizophr Bull. 2003;29(1):45-55
references.pmid: 12908660
references.citation: Curr Opin Pharmacol. 2007 Dec;7(6):643-7
references.pmid: 18024215
references.citation: Int J Obes Relat Metab Disord. 2004 Apr;28(4):470-5
references.pmid: 14993909
references.citation: Clin Neuropharmacol. 2010 Nov-Dec;33(6):288-92
references.pmid: 21060283
references.citation: Schizophr Bull. 2008 Nov;34(6):1189-99
references.pmid: 18165262
references.citation: J Psychiatr Res. 2007 Jan-Feb;41(1-2):74-9
references.pmid: 16426639
references.citation: Brain Res. 2008 Sep 16;1230:233-6
references.pmid: 18675793
references.citation: Schizophr Res. 2008 Mar;100(1-3):70-85
references.pmid: 18206351
references.citation: Arch Gen Psychiatry. 2005 Jun;62(6):649-59
references.pmid: 15939842
references.citation: Neuron. 2006 Sep 21;51(6):801-10
references.pmid: 16982424
references.citation: Neurobiol Aging. 2009 Sep;30(9):1483-9
references.pmid: 18358569